

Liver cancer

In this section, we will describe the anatomical properties of the liver and the major public health problem caused by liver cancers. This section allows us to see the potential value brought by our work regarding the treatment of liver cancer. After a small introduction about the different types of liver cancers, we will focus on the most common primary one: the **Hepatocellular Carcinoma**. We will review its risk factors, and the way it develops in the liver, before exposing the different invasive or non-invasive ways to establish a clear diagnosis of the disease. Finally we present the different staging systems and treatments available to provide the better chance of survival to the diseased patients. A precise description of the different stages of the disease and the subsequent pathological changes is necessary in order to understand how our work can further be incorporated in the clinical practice.

The liver is a key organ in the human body, responsible for the synthesis of several proteins, and playing a major role during the digestion, particularly with the production of bile that is further stored in the gallbladder. It is also essential for the breakdown of numerous hormones, and it has a central position in the human blood flow system with its unique dual blood supply, being one of the 3 only portal systems of the human body and the only venous one.

Being a key organ, the liver can suffer from various pathologies, which include liver cancer, that is now considered as a major public health challenge with its high incidence and mortality rates. In their latest statistical report, the World Health Organization ranked it as the fifth cancer type in terms of incidence with about 841,000 new cases annually, and as the fourth cause of cancer-related deaths worldwide, with about 782,000 annual deaths. Mortality and incidence rates are between 2 and 3 times higher among men than women in most regions of the world, making it the second type of cancer in terms of deaths for males [1]. More details about the complete incidence and mortality rates are illustrated in both the figure 1 & 2.

The liver cancer can either be referred to as primary, meaning that it is originally growing in the liver itself, or as secondary, in case of extrahepatic cancers that metastasize in the liver. In case of metastases, cancerous cells often originate from the lung, the breast, and some parts of the digestive system, such as the colon, with the colorectal cancer being the main source of extrahepatic metastases [3, 4]. Even though secondary liver cancers are more frequent than primary ones, we have decided to focus on the latter to analyze the entire process from the appearance of the malignant cells to the physiological changes. Indeed, analyzing secondary liver cancers requires a complete understanding of the alterations in the primary site that led to it. Primary liver cancers comprise hepatocellular carcinoma (*HCC*),




Figure 1: Estimated number of new cases in 2018, worldwide, both sexes, all ages, as described by the WHO [2]




Figure 2: Estimated number of deaths in 2018, worldwide, both sexes, all ages, as described by the WHO [2]

intrahepatic cholangiocarcinoma (*iCCA*), mixed hepatocellular cholangiocarcinoma (*HCC-CCA*) and other rare tumors, notably fibrolamellar HCC (*FLC*) and pediatric neoplasm hepatoblastoma [5–7]. HCC accounts for nearly 90% of primary liver cancers, with the highest incidence in Asia and in the Sub-Saharan countries, mainly due to the high prevalence of hepatitis B virus (*HBV*) [5,8]. The second

most common one is *iCCA*, with a noticeable high incidence in Southeast Asian countries, and mainly developed in patients with primary sclerosing cholangitis (*PSC*), biliary duct cysts, hepatolithiasis, or parasitic biliary infestation with flukes [5,9].

The high incidence of *HCC* leads us to focus our research work on this specific cancer type. We will now detail its risk factors, development, diagnosis methods and treatment techniques.

Hepatocellular Carcinoma

Risk factors

The main reason leading to *HCC* is the cirrhotic status of the liver, but its development is often related to the presence of other chronic liver diseases. Its incidence is heterogeneous worldwide because of the variable prevalence of risk factors: most cases occurring in sub-Saharan Africa and eastern Asia are associated with *HBV* and aflatoxin B1 exposure. In the USA, Europe and Japan, Hepatitis C (*HCV*) and the excessive alcohol consumption are the main risk factors [10]. Other risk factors include the presence of non alcoholic-fatty liver disease (*NAFLD*), obesity and diabetes [11]. *NAFLD* was defined about 20 years ago, and regroups a spectrum of progressive liver diseases that encompasses simple steatosis, nonalcoholic steatohepatitis (*NASH*) and ultimately cirrhosis [11]. It has been identified as the underlying cause of patients presenting with *HCC* unrelated to virus and alcohol [12]. Several other studies confirmed that *NAFLD* is a risk factor for patients with either noncirrhotic liver [13,14] or cirrhotic liver [15–17]. Obesity has been established as a risk factor for several types of cancer, including liver cancer, and a study on 900,000 American adults reported a mortality rate five times higher in patients with a body mass index of 35 kg/m² compared to the group with a normal BMI [18]. Several other studies were conducted to show the relation between HCC and obesity in the UK, Korea, Sweden, Taiwan and also a multicentric European study [19–23].

Diabetes has also been identified as an independent risk factor for HCC [10], especially types 2 diabetes [24–28].

Development

Cells of origin of liver cancer

The basic hepatic cells are divided into parenchymal (hepatocytes, which constitute between 60 and 80% of the total liver mass, and cholangiocytes as depicted in the figure 3) and non-parenchymal cells (fibroblasts, stellate cells, Kupffer cells, and endothelial cells) [5].




Figure 3: Structure of the liver lobule and location of candidate cell of origin of liver cancer. Intrahepatic organization of the liver lobule and the localization of hepatic cells that form liver tumors. Different types of cancer (ie, HCC, iCCA, mixed HCC-iCCA) can originate in the liver, depending on the transformation event and the cell type undergoing neoplastic transformation. Hepatic stem or progenitor cells are believed to reside within the most terminal branches of the biliary tree (referred to as canals of Hering). Upon injury, hepatocytes can undergo reversible ductal metaplasia and dedifferentiate into hepatocyte-derived progenitor-like cells. ©Sia et al. [5]

The two main primary liver cancers types, *HCC* and *iCCA* have been considered to be distinct tumors that originate from specific cell populations. Nonetheless, they have recently been recognized as subtypes of a continuous spectrum of diseases. Therefore, several hypotheses exist about the cells of origin of the different primary liver cancer. One of them suggests that liver tumors can be generated by hepatic progenitor cells, since during liver development, both hepatocytes and cholangiocytes both arise from a common progenitor as depicted in the figure 4. However, both tumor subtypes can also arise distinctly from mature parenchymal cells [5].

This latest hypothesis is the one that we will describe in the following, and we will focus specifically on the development of *HCCs*.

Hepatocarcinogenesis

The main process behind the evolution of *HCC* is called *hepatocarcinogenesis*, which is defined as the progressive transformation of nonmalignant liver cells into *HCC* [29]. This transformation from nonmalignant liver cells into *HCC* is not fully understood, but the chronic inflammation present in the liver results in cycles of cell injury-death-regeneration, that stimulate epidemic changes and accumulation of genetic damages [30–33]. The high inter and intra-patient heterogeneity that exists for *HCCs* is explained by the fact that several molecular variants of *HCC* may be produced, among the patients population, and even within different regions of the same tumor [33, 34]. The *hepatocarcinogenesis* is outlined by the gradual de-differentiation of abnormal nodular lesions, as described in the figure




Figure 4: Multiple cells of origin of primary liver cancers. HCC and iCCA can develop via transformation of mature hepatocytes and cholangiocytes, respectively. There is evidence that hepatic progenitor cells (HPCs), their intermediate states, or dedifferentiated hepatocytes can form liver tumors with progenitor-like features, including mixed HCC-CCA, such as CLC. Mature hepatocytes can also be reprogrammed into cells that closely resemble biliary epithelial cells and contribute to development of iCCA. ©Sia et al. [5]

5 [34, 35]. Over time, the more differentiated surrounding tissues are replaced by the growing less differentiated ones.




Figure 5: Schematic drawing illustrates typical changes in intranodular hemodynamics and OATP expression during multistep hepatocarcinogenesis. As shown, multistep hepatocarcinogenesis is characterized by successive selection and expansion of less-differentiated subnodules within more well differentiated parent nodules. The subnodules grow and eventually replace (blue arrows) the parent nodules. Progressed HCCs show expansive growth (red arrows) and characteristically are encapsulated with fibrous septa. Earlier nodules lack these structures and show replacing growth. During hepatocarcinogenesis, the density of portal triads diminishes while the density of unpaired arteries increases. ©Choi et al. [29]

It is possible that *HCCs* may arise from malignant cells without following this process, and without transitioning through histologically definable intermediate steps the process is then referred to as “*denovo* hepatocarcinogenesis” [36].

As depicted in the figure 6, hepatocarcinogenesis is composed of several steps, where each stage presents specific characteristics:

- *Cirrhotic nodules* are well-defined rounded regions of cirrhotic parenchyma surrounded by scar




Figure 6: HCC can develop inside MRNs. This type of carcinogenesis is called nodule in nodule. However, most HCCs develop outside MRNs, and precancerous lesions can be identified in areas of large and small cell dysplasia or irregular regeneration (de novo carcinogenesis). ©Trevisani et al. [33]

tissue and measuring less than 15 mm in diameter [37]. Even though they are usually considered as non-malignant, *hepatocytes* that they contain may develop dysplastic features, thus transforming the cirrhotic nodules into a *dysplastic foci* or *nodules*.

- *Dysplastic foci* are not identified via in vivo imaging, but may be recognized histologically. They are not well understood and may develop into *dysplastic nodules*.
- *Dysplastic nodules* correspond to nodular lesions that differ macro and microscopically from the surrounding parenchyma. They are observed in 25% of cirrhotic livers, and can be classified into low-grade (that appear like cirrhotic nodules) or high-grade (more similar to well-differentiated HCCs)
- *Early HCCs* grow gradually by replacing the parenchyma, unlike apparent progressed HCCs that displace or destroy the liver parenchyma. During their evolution, they tend to surround structures like portal tracts or central veins without destroying them.

They are microscopically indistinguishable from high-grade dysplastic nodules, since they tend to be vaguely nodular without having capsules nor distinct margins.

Even if they are considered as ancestors of progressed HCCs [35], their progression rate is not clearly defined [38].

- *Progressed HCCs* are generally separated between those measuring less than 2cm and those larger than 2cm.

- Those smaller than 2cm tend to be nodular with a well-defined margin. They are different from early *HCCs* in the way that they grow by expanding into and compressing the adjacent parenchyma. They tend to be histologically moderately differentiated in the vast majority of the cases, and are associated with vascular invasion and intrahepatic metastasis [35].
- The large progressed *HCCs* tend to have a more aggressive biological behavior, and are associated with a higher histological grade, with a higher presence of vascular invasion and metastasis.

They are histologically composed of poorly differentiated or undifferentiated cancer cells that spread into the surrounding sinusoids, thus often characterized by an ill-defined boundary [33, 39–45].

- *Multifocal HCC* can be the result of a synchronous development of several independent liver tumors originating from a primary tumor [33], knowing that patients with *HCC* are at higher risk of developing new tumors.

These several steps defining hepatocarcinogenesis are most of the time accompanied by some pathophysiological alterations:

- *Angiogenesis*: that is histologically characterized by the development of unpaired (or nontriadal) arteries as depicted in the Figure “hepatocarcinogenesis steps” and the transformation of hepatic sinusoids into continuous capillaries, a.k.a “sinusoidal capillarization” [46, 47].

Besides these changes, the portal tracts, containing both the non-tumoral hepatic arteries and the portal veins, progressively decrease [48].

Whereas the portal inflow to the nodule diminishes, the formation of unpaired arteries causes an increase in arterial flow [46, 47]. This difference in blood inflow is such that we observe a total inversion of tendency during the hepatocarcinogenesis, with a decrease of arterial flow accompanied by a preservation of portal venous flow in the early phases, and a decrease of portal blood flow with an increase of arterial flow in the later phases, as depicted in the figure 7.

- *Venous drainage*: During hepatocarcinogenesis, the way the blood is drained by the lesions is subject to modifications as depicted in the figure 8.

First, the blood is evacuated via hepatic veins, then sinusoids are used and replace the hepatic veins that start to be blocked. Later during the process, the sinusoids start to collapse and the blood cannot be delivered through this way, therefore, the only remaining way is through the portal veins [49, 50].




Figure 7: The net effect is that intranodular arterial supply diminishes initially and then increases (bottom graph); progressed HCCs typically show arterial hyper- vascularity compared with background liver ©Choi et al. [29]




Figure 8: Diagram of the mechanism underlying changes in drainage vessels (top) and histologic features (bottom) of HCC during multistep hepatocarcinogenesis. Top: Direction of arrow = direction of flow for that vessel type. Thickness of arrow = volume through that vessel. Wavy lines through arrow = disruption of flow. Gray area = nodule. ©Kitao et al. [49]

This change along the disease progression may explain the phenomenon of corona enhancement, which appears mainly on progressed hypervascular *HCC*, and which referred to an enhancement

of the peritumoral parenchyma starting a few seconds after the enhancement of the tumor. Worth noting that early *HCCs* are not concerned by this phenomenon [51].

- *Tumor Capsule and Fibrous Septa:* are observed in about 70% of progressed nodular *HCCs* [48], with a capsule consisting of two distinct layers.

Some studies have shown that tumors with an intact capsule were associated with a lower recurrence rate than those without (tumors of similar size), suggesting that the capsule may retard the tumor dissemination, especially the tight inner layer that might act as a physical barrier [52].

Even though advanced *HCCs* with an intact capsule have a more favorable prognosis than *HCCs* of the same size without any capsule, they have a worse prognosis than early *HCCs* that are unencapsulated [53].

- *Fat content:* It has been demonstrated that hepatocytes may accumulate fat during the early phases of hepatocarcinogenesis, causing the tumors to be more steatotic.

This steatosis is highly frequent for early *HCCs* of about 1.5 cm in diameter, but decreases when the size and the grade of the tumor increases. This might probably be because unpaired arteries become more developed once the tumor progresses, resolving ischemic conditions, and provoking the regression of steatosis [48, 54].

- *Iron content* may accumulate early in the process of hepatocarcinogenesis, noticeable essentially in low or high grade dysplastic nodules [55]. In the later stages, hepatocytes become resistant to iron accumulation due mainly to the utilization of iron by neoplastic cells and a higher cellular proliferation, thus early and progressed *HCCs* are often iron free [56].
- *Diminution in the expression of OATP Transporters.* Some of these transporters belonging to the *OATP (Organic anionic transporting polypeptides)* group are thought to be responsible for the uptake of two hepatobiliary-specific gadolinium-based contrast agents, namely the gadoxetate disodium and gadobenate dimeglumine.

Their expression level tends to be inversely proportional to the advancement of the disease [57, 58].

The different alterations are often the results of early or more advanced stages of hepatocarcinogenesis. They can appear individually or can be combined within the same tumor.

However, the *HCC* can often later spread either intra or extra-hepatically:

- *Intrahepatic metastasis:* corresponds to one of the most important spread mechanisms of progressed *HCCs*, and occurs mainly when malignant cells enter portal venules that drain the primary tumor, before spreading into the surrounding parenchyma.

These metastases around the primary tumor in the form of small satellites, and are located within its venous drainage area [59]. Even though malignant cells can easily invade vessels, extrahepatic metastases occurring in organs such as the lungs, the lymph nodes, the bones or the adrenal glands, are late manifestations of the disease [33, 45].

- *Vascular invasion:* is a late manifestation of hepatocarcinogenesis, affecting mainly the progressed *HCCs* [60], and allows a distinction between primary and secondary liver cancers which uncommonly present an invasion of intrahepatic vessels [61].

These invasions are either classified as micro or macroscopic, and usually are accompanied by a poor prognosis, as they provide a way for cancerous cells to propagate in the liver or systemically. Moreover, patients suffering from cancers with vascular invasion tend to have a higher recurrence rate after ablation, resection and transplantation, therefore, vascular invasion is often considered as a contraindication for these specific treatments [62].

Furthermore, another alteration, called “*Tumor Capsule invasion*” may increase the risk of vascular invasion, as *HCC* cells may infiltrate through the tumor capsule into the surrounding parenchyma.

All the changes occurring during hepatocarcinogenesis, leading to a more or less aggressive tumor, or even to multiple tumors, need to be assessed as early as possible to provide the best treatment available to the patient in order to increase its chances of survival.

Diagnosis

Biopsy

One of the standard ways to determine or confirm the cause and the stage of liver disease, as well as to inform treatment decisions and establish prognosis is to perform a *biopsy*. This surgical procedure consists of the sampling of a specimen measuring typically between 1 and 3 cm in length, with a diameter comprised between 1.2 and 2 mm [63].

The sampled tissues are then reviewed by pathologists, who report the degree of inflammation, steatosis, fibrosis and some other features such as cellular inclusions. The histological assessment is supported by clinicians providing the clinical context to complete the histologic interpretation, and some external blood markers such as the *AFP* (alpha-fetoprotein) level can be incorporated to attest the presence of a malignant mass [64, 65].

This method however suffers from several limitations. Sampling errors are common, as reported by a study where laparoscopic biopsy samples, taken simultaneously from the right and the left lobes of

several patients suffering from HCV, were interpreted as cirrhotic in one lobe and fibrotic (F3) in the other in almost 15% of the cases [66]. It has also been proven that the accuracy of both the diagnosis and the staging of the disease highly depend on the size of the specimen, with misinterpretations when too small samples are collected [67].

The interpretation of the samples is very subjective as it has been proven in some studies, with the estimation of both inflammatory activity and fat burden that suffered from a high inter and intraobserver variability [68]. Moreover, being a surgical gesture, the biopsy can suffer from adverse events going from simple pain to death in some rare cases [69–72]. Finally, they happen to be costly since they involve an expert gastroenterologist or radiologist, a pathologist, and need to be performed in facilities with adequate equipment.

Even though biopsy is still used to evaluate the degree of fibrosis or cirrhosis, primary liver cancers are now most often diagnosed on the basis of imaging studies alone in clinical practice. Recent advancements in medical imaging enable the radiologist to discern the cause of focal liver lesions on the basis of vascularity and physiological features, especially through multiphasic, contrast-enhanced, cross-sectional imaging (either computed tomography *CT*, or magnetic resonance *MR*).

CT and MR imaging

As explained previously, hepatocarcinogenesis is a long process that can render the tumor very aggressive, and the more the disease evolves, the worse the prognosis will be for the patient, thus an early detection of HCC is critical to improve the survival of affected patients.

The majority of the current guidelines recommend ultrasonography (US) as the primary imaging test for surveillance [29]. CT and MRI are generally not chosen for surveillance but recommended by some guidelines when the US is limited due to obesity or when the risk factors are very high [73, 74].

If the surveillance is positive, the main guidelines advocate in favor of multiphasic CT and MR with extracellular agents for the non-invasive diagnosis and staging [39, 73–75].

Multiphasic CT and MRI can be categorized by the type of contrast agents used:

- Imaging with extracellular contrast agents permits a diagnosis of *HCC* based on the physiological changes in the blood flow produced by hepatocarcinogenesis.

Images are typically acquired before (precontrast) and dynamically after the injection of a contrast agent.

The contrast agent is generally administered at a rate of 4-6 mL/sec for CT and around 2 mL/sec for MRI [76, 77]. The dose is usually adjusted to the body weight, where 1.5-2 mL/kg to achieve

an iodine dose of 525 mg/kg of iodine are administered in the case of CT.

Concerning the dynamic contrast enhanced images, three phases are typically acquired, namely the late hepatic arterial, the portal venous, and the delayed phase as illustrated in the figure 9:

- The *late hepatic arterial* phase is characterized by the full enhancement of the hepatic artery with all its branches and an enhancement of the portal vein [29]. The portal vein is however not supposed to be enhanced by the antegrade flow [78].

This phase is critical for the characterization of hypervascular *HCCs*, since it catches the peak arterial enhancement of tumors [79]. The *early hepatic arterial* phase is often omitted by the centers as only hepatic arteries are enhanced but portal veins are not, which render the detection of hypervascular tumors very difficult. One of the main problems associated with this acquisition is the difficulty to detect the peak arterial perfusion, since fixed delay is often not reliable. Some techniques such as contrast agent bolus tracking, or the selection of the best image after multiple continuous acquisitions may be recommended [80].

- The *portal venous* phase is characterized by an enhancement of both hepatic artery (arterial) and portal veins. It is however worth noting that the contrast agent still circulates in the body and will still be present in hepatic arteries as well (but with a lower concentration than for the arterial phases).

The portal venous phase is generally acquired at around 60-80 seconds after the start of the injection, but no clear guidelines are given concerning a precise way to determine the best moment for the acquisition of this given phase.

- The *delayed phase* is acquired 3-5 minutes after the injection and helps to understand how the liver restores the contrast agent back to the rest of the body, especially in case of inhomogeneous washout.

Both the *portal venous* and the *delayed* phases are critical for the characterization of washout and/or capsule appearance, and are crucial for the differentiation of small *HCCs* from small *ICCs* [82, 83]. Some centers decide to skip the delayed phase, but it can lead to a loss of information.

Precontrast images are useful in case of detection of enhancement and evaluation of its degree by subtracting the post-contrast image with the precontrast one. They are also useful for patients with iron-rich nodules to detect hyper attenuation before injection of contrast agent, thus avoiding misinterpretation of arterial phase enhancement.

In addition to these classical vascular phases, examinations performed with MR imaging usually include other phases such as the T1-weighted in-phase, the T2-weighted fast-spin-echo and some




Figure 3: Images in a 64-year-old man with infiltrative HCC and macrovascular invasion. Axial CT images obtained in the (a) late arterial, (b) portal venous, and (c) 3-minute delayed phases after administration of an iodinated contrast agent reveal heterogeneously enhancing soft tissue expanding the lumen of the right portal vein and its branches consistent (arrowheads) with macrovascular invasion by HCC. Note arterial phase hyperenhancing tumoral arteries (arrows), sometimes described as “threads and streaks,” within the intraluminal tissue. Note patchy areas (*) of arterial phase hyperenhancement and delayed phase partial washout appearance in the liver parenchyma, consistent with infiltrative HCC.

Figure 9: Example of computed tomography images of patients suffering from infiltrative HCC with macrovascular invasion. ©Choi et al. 2014 [81]

diffusion-weighted sequences.

- In order to fully understand the behavior of *HCC* cells, one can use extracellular agents as explained above, or use intracellular agents. In the latter case, hepatobiliary agents allow a better diagnosis through understanding the hepatocellular function in addition to the vascularity information. These agents first enhance the extracellular space before entering the hepatocytes through the OATP specific receptors. To acquire this hepatobiliary phase, which can exclusively be obtained on MRI, different agents exist, and they mainly differ in their hepatocellular uptake, thus reaching an enhancement at different moments. In the exception to the delayed phase for some specific agents, the normal phases can be acquired, along with some new phases such as the “transitional phase”, which represent a transition from extracellular-dominant to intracellular-dominant enhancement [84]. Examples of images obtained with after a multiphasic MR examination are illustrated in the figure 10

Unlike extracellular agents, the hepatobiliary contrast agents show promise for differentiating early *HCCs* and premalignant nodules from lower-risk nodules [85–91].

Main advantages of choosing CT over MRI examination is that it is widely available, rapid, robust and requires less expertise than MRI when interpreting images. It however exposes patients to radiation doses, and provides relatively lower soft-tissue contrast than when MRI is used. MRI permits the assessment of a great number of tissue characteristics, but is time-consuming, less robust, and prone to artifacts. Even though MR imaging examination may be preferred at some academic centers, there is no consensus for recommending this modality over CT in community or less-specialized centers [65,81].




Figure 4: Images in 42-year-old man with HCC and hepatitis B-related cirrhosis: multiphasic MR technique with gadobutrol disodium. **(a, b)** Gadobutrol disodium-enhanced T1-weighted 3D GRE images (2.5/0.9; flip angle, 11°) show large hypointense mass on **(a)** precontrast image with **(b)** hyperenhancement in late hepatic arterial phase. **(c)** Portal venous and **(d)** transitional phase images show apparent washout of contrast material from tumor. **(e)** Mass is hypointense relative to strongly enhanced liver parenchyma on hepatobilary phase image obtained at 20 minutes after injection. Surgical specimen confirmed progressed HCC with perilesional satellite metastases. Metastases were visible on other MR sections (not shown). Histologically, tumor was poorly differentiated (Edmondson grade III).

Figure 10: Example of multiphasic MR images of a patient suffering from HCC, ©Choi et al. [81]

Therefore, it has been decided to mainly focus our research work on CT images.

These recent innovations in the medical imaging fields were accompanied by the creation of several clinical criteria that helped the radiologists to take decisions concerning the treatment choice, depending mainly on the characteristics of the tumor.

Staging & Treatment

One of the most widely used criteria for the assessment of *HCCs* is the *BCLC* staging system, recently refined by Llovet et al. in 2008, and illustrated in the figure 11 [92].

As described in the figure below, the main factors used to build this staging system rely on the *tumor status*, namely, the number and the size of the nodules, the presence or the absence of vascular invasion and extrahepatic spread. Other characteristics such as the *liver function* (as defined by the Child-Pugh classification [93], the potential presence of portal hypertension and both serum bilirubin and albumin levels), and an indicator called the *general performance status* describing the overall level of functioning of the patient [94].

These criteria were developed to support previous staging systems such as the *TNM* as depicted in the figure 12, that was introduced and refined by the AJCC, and it incorporated some independent work such as the *Milan criteria* which concerns only a specific subtype of the *TNM* staging system [95].

One of the main advantages brought by the *BCLC* staging system is to provide strong guidelines concerning the treatments to follow depending on the disease progression. Hereafter, we detail the




Fig. 1 Barcelona Clinic Liver Cancer staging classification and treatment schedule (Llovet et al. 2008a)

Figure 11: BCLC staging classification, as illustrated by Llovet et al. ©Llovet et al. [92]

Primary Tumor (T)	
TX	Primary tumor cannot be assessed
T0	No evidence of primary tumor
T1	Solitary tumor without vascular invasion
T2	Solitary tumor with vascular invasion or multiple tumors none more than 5 cm
T3a	Multiple tumors more than 5 cm
T3b	Single tumor or multiple tumors of any size involving a major branch of the portal vein or hepatic vein
T4	Tumor(s) with direct invasion of adjacent organs other than the gallbladder or with perforation of visceral peritoneum
Regional Lymph Nodes (N)	
NX	Regional lymph nodes cannot be assessed
N0	No regional lymph node metastasis
N1	Regional lymph node metastasis
Distant Metastasis (M)	
M0	No distant metastasis
M1	Distant metastasis

Figure 12: TNM classification as described by the ©AJCC Cancer Staging [96]

different treatment techniques available for patients suffering from *HCCs* when seeking for curation:

- *Surgical resection*, where the best candidates are patients with solitary tumor and preserved liver functions [10].

A resection is defined as curative if all macroscopic evidence of primary and second tumor are detected in the remnant liver or in any other organs by dynamic CT or MR within 4 weeks after surgery [97].

As mentioned by previous studies, resection remains the treatment of choice in patients without cirrhosis suffering from HCC. Patients with cirrhosis have to be carefully selected to reduce the risk of postoperative liver failure [74, 75, 98].

- *Liver transplantation*, which mainly benefits patients who are not good candidates for surgical resection, and fits better those within the *Milan criteria* (solitary tumor up to 5cm or less than 3 nodules measuring each one less than 3cm) [74, 99]. In theory the transplantation may cure the tumor and the underlying cirrhosis at the same time, however, this procedure suffers from

a scarcity in terms of donors, with an increase in the waiting time that led up to 20% of the potential receivers to drop out of the list before finding a donor, even with the existence of bridge therapies that can preserve the patient health during the waiting time [100].

Some modifications have been done to the initial inclusion criteria for the transplant candidates after poor recurrence results were obtained [74].

- Image-guided ablation (*IGA*) is the most frequently used therapeutic strategy but its efficacy is limited by the size of the tumor and its location.

This technique belongs, just like resections, to primary line treatments for patients with early stage *HCC* (BCLC stage 0-A) for whom surgical management is contraindicated [65, 75]. It has also been noticed that patients with very small *HCCs* (less than 2cm in diameter) can benefit from *IGA* to avoid any surgical procedure [101].

Several methods have been developed to perform the destruction of the tumor, and radiofrequency ablation (*RFA*) remains the most popular technique. Other techniques (thermal or non-thermal) have been adopted to overcome limitations of *RFA*.

The risk of complications is higher when the procedure is performed on tumors located along the surface of the liver. Indeed, puncture can cause bleeding, and heating can cause complications by provoking injury on adjacent organs. The intervention should be performed by an oncologist with sufficient experience, in order to assess the risk of causing damages to the gastrointestinal tract [102].

However, *RFA* techniques have recently been improved by the assistance of 3D navigation systems, allowing better planning with multiple overlapping ablation zones, a more accurate placement of the probes and an assessment of the results intraoperatively, thanks to image fusion. This new generation of techniques is called “*stereotactic RFA*” [103–105].

Therefore, the question whether to choose resection over *RFA* is still open [65, 104].

- Transarterial Chemoembolization (*TACE*), which has survival benefits in asymptomatic patients with multifocal disease without vascular invasion or extrahepatic spread can also be considered [10]. *TACE* can also be applied to patients in earlier stages, who are not suitable for the other therapeutic available treatments. This clinical situation is known as “treatment stage migration” and reflects a certain flexibility in the *BCLC* clinical interpretation [106].

The same staging systems are used for the patient follow-up, and can be supported by other metrics such as the *RECIST* (standing for “*Response evaluation criteria in solid tumours*”) which assess the tumor response, but presents several limitations and has already been modified in the past to incorporate changes [107].

As explained here, general staging systems rely mainly on the macro changes caused by the disease, ignoring many histological measurements, such as the histological grade, depicted in the figure 13, and defined following the Edmonson-Steiner grading system, corresponding to the level of cellular differentiation [60]:

- G1: Well differentiated
- G2: Moderately differentiated
- G3: Poorly differentiated
- G4: Undifferentiated




Figure 13: Histological grades as illustrated by ©Turdean et al. [108]

Current methods to evaluate the tumor and to propose the best available treatment still suffer from a lot of limitations, especially because they rely on subjective interpretation of images, or clinical data, and also because of the discrete staging systems that are used in a clinical routine.

The main hypothesis of our research work is that medical images can be enhanced to provide a subjective feedback to the clinicians, and help them with non-invasive tools to give to patients suffering from *HCCs* the best chances of survival.

(Add a short introduction to radiomics here)

References

- [1] F. Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L. Siegel;, Lindsey A. Torre;, and Ahmedin Jemal. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA: A Cancer Journal for Clinicians*, 2018.
- [2] World health organization. Accessed: 2020-10-20.
- [3] Morten Høyer, Anand Swaminath, Sean Bydder, Michael Lock, Alejandra Méndez Romero, Brian Kavanagh, Karyn A. Goodman, Paul Okunieff, and Laura A. Dawson. Radiotherapy for liver metastases: A review of evidence. *International Journal of Radiation Oncology Biology Physics*, 82(3):1047–1057, 2012.
- [4] Dushyant V. Sahani, Mohammad Ali Bajwa, Yasir Andrabi, Surabhi Bajpai, and James C. Cusack. Current status of imaging and emerging techniques to evaluate liver metastases from colorectal carcinoma. *Annals of Surgery*, 259(5):861–872, 2014.
- [5] Daniela Sia, Augusto Villanueva, Scott L. Friedman, and Josep M. Llovet. Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis. *Gastroenterology*, 152(4):745–761, 2017.
- [6] Rafael Lozano, Mohsen Naghavi, Kyle Foreman, Stephen Lim, Kenji Shibuya, Victor Aboyans, Jerry Abraham, Timothy Adair, Rakesh Aggarwal, Stephanie Y. Ahn, Mohammad A. AlMazroa, Miriam Alvarado, H. Ross Anderson, Laurie M. Anderson, Kathryn G. Andrews, Charles Atkinson, Larry M. Baddour, Suzanne Barker-Collo, David H. Bartels, Michelle L. Bell, Emelia J. Benjamin, Derrick Bennett, Kavi Bhalla, Boris Bikbov, Aref Bin Abdulhak, Gretchen Birbeck, Fiona Blyth, Ian Bolliger, Soufiane Boufous, Chiara Bucello, Michael Burch, Peter Burney, Jonathan Carapetis, Honglei Chen, David Chou, Sumeet S. Chugh, Luc E. Coffeng, Steven D. Colan, Samantha Colquhoun, K. Ellicott Colson, John Condon, Myles D. Connor, Leslie T. Cooper, Matthew Corriere, Monica Cortinovis, Karen Courville De Vaccaro, William Couser, Benjamin C. Cowie, Michael H. Criqui, Marita Cross, Kaustubh C. Dabhadkar, Nabila Dahodwala, Diego De Leo, Louisa Degenhardt, Allyne Delossantos, Julie Denenberg, Don C. Des Jarlais, Samath D. Dharmaratne, E. Ray Dorsey, Tim Driscoll, Herbert Duber, Beth Ebel, Patricia J. Erwin, Patricia Espindola, Majid Ezzati, Valery Feigin, Abraham D. Flaxman, Mohammad H. Forouzanfar, Francis Gerry R. Fowkes, Richard Franklin, Marlene Fransen, Michael K. Freeman, Sherine E. Gabriel, Emmanuel Gakidou, Flavio Gaspari, Richard F. Gillum, Diego Gonzalez-Medina, Yara A. Halasa, Diana Haring, James E. Harrison, Rasmus Havmoeller, Roderick J. Hay, Bruno Hoen, Peter J.

Hotez, Damian Hoy, Kathryn H. Jacobsen, Spencer L. James, Rashmi Jasrasaria, Sudha Jayaraman, Nicole Johns, Ganesan Karthikeyan, Nicholas Kassebaum, Andre Keren, Jon Paul Khoo, Lisa Marie Knowlton, Olive Kobusingye, Adofo Koranteng, Rita Krishnamurthi, Michael Lipnick, Steven E. Lipshultz, Summer Lockett Ohno, Jacqueline Mabweijano, Michael F. MacIntyre, Leslie Mallinger, Lyn March, Guy B. Marks, Robin Marks, Akira Matsumori, Richard Matzopoulos, Bongani M. Mayosi, John H. McAnulty, Mary M. McDermott, John McGrath, Ziad A. Memish, George A. Mensah, Tony R. Merriman, Catherine Michaud, Matthew Miller, Ted R. Miller, Charles Mock, Ana Olga Mocumbi, Ali A. Mokdad, Andrew Moran, Kim Mulholland, M. Nathan Nair, Luigi Naldi, K. M. Venkat Narayan, Kiumarss Nasseri, Paul Norman, Martin O'Donnell, Saad B. Omer, Katrina Ortblad, Richard Osborne, Doruk Ozgediz, Bishnu Pahari, Jeyaraj Durai Pandian, Andrea Panozo Rivero, Rogelio Perez Padilla, Fernando Perez-Ruiz, Norberto Perico, David Phillips, Kelsey Pierce, C. Arden Pope, Esteban Porrini, Farshad Pourmalek, Murugesan Raju, Dharani Ranganathan, Jürgen T. Rehm, David B. Rein, Giuseppe Remuzzi, Frederick P. Rivara, Thomas Roberts, Felipe Rodriguez De León, Lisa C. Rosenfeld, Lesley Rushton, Ralph L. Sacco, Joshua A. Salomon, Uchechukwu Sampson, Ella Sanman, David C. Schwebel, Maria Segui-Gomez, Donald S. Shepard, David Singh, Jessica Singleton, Karen Sliwa, Emma Smith, Andrew Steer, Jennifer A. Taylor, Bernadette Thomas, Imad M. Tleyjeh, Jeffrey A. Towbin, Thomas Truelsen, Eduardo A. Undurraga, N. Venketasubramanian, Lakshmi Vijayakumar, Theo Vos, Gregory R. Wagner, Mengru Wang, Wenzhi Wang, Kerrianne Watt, Martin A. Weinstock, Robert Weintraub, James D. Wilkinson, Anthony D. Woolf, Sarah Wulf, Pon Hsiu Yeh, Paul Yip, Azadeh Zabetian, Zhi Jie Zheng, Alan D. Lopez, and Christopher J.L. Murray. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010. *The Lancet*, 380(9859):2095–2128, 2012.

- [7] F. T. Bosman, F. Carneiro, R. H. Hruban, and N. D. Theise. *WHO classification of tumours of the digestive system*. Number Ed. 4. World Health Organization, Geneva, Switzerland, 2010.
- [8] Lindsey A. Torre, Freddie Bray, Rebecca L. Siegel, Jacques Ferlay, Joannie Lortet-Tieulent, and Ahmedin Jemal. Global cancer statistics, 2012. *CA: A Cancer Journal for Clinicians*, 65(2):87–108, 2015.
- [9] John Bridgewater, Peter R. Galle, Shahid A. Khan, Josep M. Llovet, Joong Won Park, Tushar Patel, Timothy M. Pawlik, and Gregory J. Gores. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. *Journal of Hepatology*, 60(6):1268–1289, 2014.
- [10] Alejandro Forner, María Reig, and Jordi Bruix. Hepatocellular carcinoma. *The Lancet*, 391(10127):1301–1314, apr 2018.

- [11] Andrea Marengo, Chiara Rosso, and Elisabetta Bugianesi. Liver Cancer: Connections with Obesity, Fatty Liver, and Cirrhosis. *Annual Review of Medicine*, 67(1):103–117, 2016.
- [12] Jorge A. Marrero, Robert J. Fontana, Grace L. Su, Hari S. Conjeevaram, Dawn M. Emick, and Anna S. Lok. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. *Hepatology*, 36(6):1349–1354, 2002.
- [13] Valérie Paradis, Stéphane Zalinski, Emma Chelbi, Nathalie Guedj, Françoise Degos, Valérie Vilgrain, Pierre Bedossa, and Jacques Belghiti. Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liverfibrosis: A pathological analysis. *Hepatology*, 49(3):851–859, 2009.
- [14] Jessica Dyson, Bryan Jaques, Dipankar Chattpadyhay, Rajiv Lochan, Janine Graham, Debasish Das, Tahira Aslam, Imran Patanwala, Sameer Gaggar, Michael Cole, Kate Sumpter, Stephen Stewart, John Rose, Mark Hudson, Derek Manas, and Helen L. Reeves. Hepatocellular cancer: The impact of obesity, type 2 diabetes and a multidisciplinary team. *Journal of Hepatology*, 60(1):110–117, 2014.
- [15] Robert J. Wong, Ramsey Cheung, and Aijaz Ahmed. Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S. *Hepatology*, 59(6):2188–2195, 2014.
- [16] Mustafa S. Ascha, Ibrahim A. Hanouneh, Rocio Lopez, Tarek Abu Rajab Tamimi, Ariel F. Feldstein, and Nizar N. Zein. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. *Hepatology*, 51(6):1972–1978, 2010.
- [17] Sahil Mittal, Yvonne H. Sada, Hashem B. El-Serag, Fasiha Kanwal, Zhigang Duan, Sarah Temple, Sarah B. May, Jennifer R. Kramer, Peter A. Richardson, and Jessica A. Davila. Temporal trends of nonalcoholic fatty liver disease-related hepatocellular carcinoma in the veteran affairs population. *Clinical Gastroenterology and Hepatology*, 13(3):594–601.e1, 2015.
- [18] Eugenia E. Calle, Carmen Rodriguez, Kimberly Walker-Thurmond, and Michael J. Thun. Overweight, Obesity, and Mortality from Cancer in a Prospectively Studied Cohort of U.S. Adults. *New England Journal of Medicine*, 348(17):1625–1638, apr 2003.
- [19] Chi Ling Chen, Hwai I. Yang, Wei Shiung Yang, Chun Jen Liu, Pei Jer Chen, San Lin You, Li Yu Wang, Chien An Sun, Sheng Nan Lu, Ding Shin Chen, and Chien Jen Chen. Metabolic Factors and Risk of Hepatocellular Carcinoma by Chronic Hepatitis B/C Infection: A Follow-up Study in Taiwan. *Gastroenterology*, 135(1):111–121, 2008.

- [20] Sabrina Schlesinger, Krasimira Aleksandrova, Tobias Pischon, Veronika Fedirko, Mazda Jenab, Elisabeth Trepo, Paolo Boffetta, Christina C Dahm, Kim Overvad, Anne Tjønneland, Jytte Halkjær, and Guy Fagherazzi. Abdominal obesity , weight gain during adulthood and risk of liver and biliary tract cancer in a European Cohort. 000(May), 2012.
- [21] Claudine Samanic, Wong Ho Chow, Gloria Gridley, Bengt Jarvholm, and Joseph F. Fraumeni. Relation of body mass index to cancer risk in 362,552 Swedish men. *Cancer Causes and Control*, 17(7):901–909, 2006.
- [22] Sang Woo Oh, Yeong Sook Yoon, and Soon Ae Shin. Effects of excess weight on cancer incidences depending on cancer sites and histologic findings among men: Korea National Health Insurance Corporation study. *Journal of Clinical Oncology*, 23(21):4742–4754, 2005.
- [23] G. D. Batty, M. J. Shipley, R. J. Jarrett, E. Breeze, M. G. Marmot, and G. Davey Smith. Obesity and overweight in relation to organ-specific cancer mortality in London (UK): Findings from the original Whitehall study. *International Journal of Obesity*, 29(10):1267–1274, 2005.
- [24] Hiroshi Noto, Keiichiro Osame, Takehiko Sasazuki, and Mitsuhiko Noda. Substantially increased risk of cancer in patients with diabetes mellitus: A systematic review and meta-analysis of epidemiologic evidence in Japan. *Journal of Diabetes and its Complications*, 24(5):345–353, 2010.
- [25] Louise Wideroff, Gloria Gridley, Lene Mellemkjaer, W. H. Chow, Martha Linet, Shannon Keehn, Knut Borch-Johnsen, and Jørgen H. Olsen. Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in denmark. *Journal of the National Cancer Institute*, 89(18):1360–1365, 1997.
- [26] Hashem B. El-Serag, Thomas Tran, and James E. Everhart. Diabetes Increases the Risk of Chronic Liver Disease and Hepatocellular Carcinoma. *Gastroenterology*, 126(2):460–468, 2004.
- [27] J. A. Davila, R. O. Morgan, Y. Shaib, K. A. McGlynn, and H. B. El-Serag. Diabetes increases the risk of hepatocellular carcinoma in the United States: A population based case control study. *Gut*, 54(4):533–539, 2005.
- [28] Manami Inoue. Diabetes Mellitus and the Risk of Cancer. *Archives of Internal Medicine*, 166(17):1871, sep 2006.
- [29] Jin Young Choi, Jeong Min Lee, and Claude B. Sirlin. CT and MR imaging diagnosis and staging of hepatocellular carcinoma: Part I. Development, growth, and spread: Key pathologic and imaging aspects. *Radiology*, 272(3):635–654, 2014.

- [30] Snorri S. Thorgeirsson and Joe W. Grisham. Molecular pathogenesis of human hepatocellular carcinoma. *Nature Genetics*, 31(4):339–346, 2002.
- [31] Rajagopal N. Aravalli, Erik N.K. Cressman, and Clifford J. Steer. Cellular and molecular mechanisms of hepatocellular carcinoma: An update. *Archives of Toxicology*, 87(2):227–247, 2013.
- [32] Rachel I. Brody and Neil D. Theise. An inflammatory proposal for hepatocarcinogenesis. *Hepatology*, 56(1):382–384, jul 2012.
- [33] Franco Trevisani, M. C. Cantarini, J. R. Wands, and M. Bernardi. Recent advances in the natural history of hepatocellular carcinoma. *Carcinogenesis*, 29(7):1299–1305, 2008.
- [34] Catherine Frenette and Robert G. Gish. Hepatocellular Carcinoma: Molecular and Genomic Guideline for the Clinician. *Clinics in Liver Disease*, 15(2):307–321, 2011.
- [35] Young Nyun Park. Update on precursor and early lesions of hepatocellular carcinomas. *Archives of Pathology and Laboratory Medicine*, 135(6):704–715, 2011.
- [36] Ken Ichi Taguchi, Yoshiki Asayama, Shin Ichi Aishima, Hidehiro Nishi, Keishi Sugimachi, Shuji Matsuura, Takahiro Terashi, Takeharu Yamanaka, Mitsuo Shimada, Keizo Sugimachi, and Masazumi Tsuneyoshi. Morphologic approach to hepatocellular carcinoma development in man: De novo or the so-called 'dysplastic nodule-carcinoma' sequence? *Oncology Reports*, 9(4):737–743, July 2002.
- [37] A. Zimmermann. Terminology of nodular hepatocellular lesions. *Hepatology*, 22(3):983–993, sep 1995.
- [38] Korosh Khalili, Tae Kyoung Kim, Hyun Jung Jang, Leyla Kochak Yazdi, Maha Guindi, and Morris Sherman. Indeterminate 1-2-cm nodules found on hepatocellular carcinoma surveillance: Biopsy for all, some, or none? *Hepatology*, 54(6):2048–2054, 2011.
- [39] Masatoshi Kudo. Real practice of hepatocellular carcinoma in Japan: Conclusions of the Japan society of hepatology 2009 kobe congress. *Oncology*, 78(SUPPL. 1):180–188, 2010.
- [40] R.Palmer Beasley, Chia-Chin Lin, Lu-Yu Hwang, and Chia-Siang Chien. HEPATOCELLULAR CARCINOMA AND HEPATITIS B VIRUS. *The Lancet*, 318(8256):1129–1133, nov 1981.
- [41] Hashem B. El-Serag. Hepatocellular Carcinoma. *New England Journal of Medicine*, 365(12):1118–1127, sep 2011.

- [42] György Baffy, Elizabeth M. Brunt, and Stephen H. Caldwell. Hepatocellular carcinoma in non-alcoholic fatty liver disease: An emerging menace. *Journal of Hepatology*, 56(6):1384–1391, 2012.
- [43] Katherine A. McGlynn and W. Thomas London. The Global Epidemiology of Hepatocellular Carcinoma: Present and Future. *Clinics in Liver Disease*, 15(2):223–243, 2011.
- [44] Gia L. Tyson and Hashem B. El-Serag. Risk factors for cholangiocarcinoma. *Hepatology*, 54(1):173–184, 2011.
- [45] Neil Theise, M.P. Curado, and S. Franceschi. Hepatocellular carcinoma. *WHO Classification of Tumours of the Digestive System*, pages 205–216, 01 2010.
- [46] William C. Palmer and Tushar Patel. Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma. *Journal of Hepatology*, 57(1):69–76, 2012.
- [47] William B. Coleman. Mechanisms of Human Hepatocarcinogenesis. *Current Molecular Medicine*, 3(6):573–588, 2005.
- [48] Masamichi Kojiro and Tania Roskams. Early hepatocellular carcinoma and dysplastic nodules. *Seminars in Liver Disease*, 25(2):133–142, 2005.
- [49] Azusa Kitao, Yoh Zen, Osamu Matsui, Toshifumi Gabata, and Yasuni Nakanuma. Hepatocarcinogenesis : Multistep Changes of Drainage Vessels at CT during Arterial Portography and Purpose : Methods : Results : Conclusion :. *Ra*, 252(2):605–614, 2009.
- [50] Kazuhiko Ueda, Osamu Matsui, Yasuhiro Kawamori, Yasuni Nakanuma, Masumi Kadoya, Jun Yoshikawa, Toshifumi Gabata, Akitaka Nonomura, and Tsutomu Takashima. Hypervascular hepatocellular carcinoma: Evaluation of hemodynamics with dynamic CT during hepatic arteriography. *Radiology*, 206(1):161–166, 1998.
- [51] Osamu Matsui, Satoshi Kobayashi, Junichiro Sanada, Wataru Kouda, Yasuji Ryu, Kazuto Kozaka, Azusa Kitao, Koichi Nakamura, and Toshifumi Gabata. Hepatocelluar nodules in liver cirrhosis: Hemodynamic evaluation (angiography-assisted CT) with special reference to multi-step hepatocarcinogenesis. *Abdominal Imaging*, 36(3):264–272, 2011.
- [52] Irene O.L. Ng, Edward C.S. Lai, Sheung T. Fan, and Matthew M.T. Ng. Tumor encapsulation in hepatocellular carcinoma. A pathologic study of 189 cases. *Cancer*, 70(1):45–49, 1992.
- [53] Tomohiro Iguchi, Shinichi Aishima, Kensaku Sanefuji, Nobuhiro Fujita, Keishi Sugimachi, Tomonobu Gion, Akinobu Taketomi, Ken Shirabe, Yoshihiko Maehara, and Masazumi Tsuneyoshi.

Both fibrous capsule formation and extracapsular penetration are powerful predictors of poor survival in human hepatocellular carcinoma: A histological assessment of 365 patients in Japan. *Annals of Surgical Oncology*, 16(9):2539–2546, 2009.

- [54] Rumiko Kutami, Yutaka Nakashima, Osamu Nakashima, Koji Shiota, and Masamichi Kojiro. Pathomorphologic study on the mechanism of fatty change in small hepatocellular carcinoma of humans. *Journal of Hepatology*, 33(2):282–289, 2000.
- [55] Masamichi Kojiro, Ian R. Wanless, Venancio Alves, Sunil Badve, Charles Balabaud, Pierre Bedosa, Prithi Bhathal, Paulette Bioulac-Sage, Elizabeth M. Brunt, Alastair D. Burt, John R. Craig, Amar Dhillon, Linda Ferrell, Stephen A. Geller, Zackary D. Goodman, Annette S.H. Gouw, Maria Guido, Maha Guindi, Prodromos Hytiroglou, Masayoshi Kage, Fukuo Kondo, Masatoshi Kudo, Gregory Y. Lauwers, Masayuki Nakano, Valerie Paradis, Young Nyun Park, Alberto Quaglia, Massimo Roncalli, Tania Roskams, Boris Ruebner, Michiie Sakamoto, Romil Saxena, Neil D. Theise, Swan Thung, and Dina Taniakos. Pathologic diagnosis of early hepatocellular carcinoma: A report of the international consensus group for hepatocellular neoplasia. *Hepatology*, 49(2):658–664, feb 2009.
- [56] Kurinchi Gurusamy. Trace element concentration in primary liver cancers - A systematic review. *Biological Trace Element Research*, 118(3):191–206, 2007.
- [57] Azusa Kitao, Osamu Matsui, Norihide Yoneda, Kazuto Kozaka, Rieko Shinmura, Wataru Koda, Satoshi Kobayashi, Toshifumi Gabata, Yoh Zen, Tatsuya Yamashita, Shuichi Kaneko, and Yasuni Nakanuma. The uptake transporter OATP8 expression decreases during multistep hepatocarcinogenesis: Correlation with gadoxetic acid enhanced MR imaging. *European Radiology*, 21(10):2056–2066, 2011.
- [58] Takahiro Tsuboyama, Hiromitsu Onishi, Tonsok Kim, Hirofumi Akita, Masatoshi Hori, Mitsuaki Tatsumi, Atsushi Nakamoto, Hiroaki Nagano, Nariaki Matsuura, Kenichi Wakasa, and Kaname Tomoda. Hepatocellular carcinoma: Hepatocyte-selective enhancement at gadoxetic acid-enhanced MR imaging - Correlation with expression of sinusoidal and canalicular transporters and bile accumulation. *Radiology*, 255(3):824–833, 2010.
- [59] Yutaka Nakashima, Osamu Nakashima, Masatoshi Tanaka, Koji Okuda, Miwako Nakashima, and Masamichi Kojiro. Portal vein invasion and intrahepatic micrometastasis in small hepatocellular carcinoma by gross type. *Hepatology Research*, 26(2):142–147, 2003.
- [60] Steiner Edmondson HA and PE. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. *Cancer*, 7(3):462–503, 1954.

- [61] Kunio Okuda. Hepatocellular carcinoma: Clinicopathological aspects. *Journal of Gastroenterology and Hepatology (Australia)*, 12(9-10):314–318, 1997.
- [62] Josep M. Llovet, Josep Fuster, and Jordi Bruix. The Barcelona approach: Diagnosis, staging, and treatment of hepatocellular carcinoma. *Liver Transplantation*, 10(2 SUPPL. 1):115–120, 2004.
- [63] Arturo A. Bravo, Sunil G. Sheth, and Sanjiv Chopra. Liver Biopsy. *New England Journal of Medicine*, 344(7):495–500, feb 2001.
- [64] Dou Sheng Bai, Chi Zhang, Ping Chen, Sheng Jie Jin, and Guo Qing Jiang. The prognostic correlation of AFP level at diagnosis with pathological grade, progression, and survival of patients with hepatocellular carcinoma. *Scientific Reports*, 7(1):1–9, 2017.
- [65] Julie K. Heimbach, Laura M. Kulik, Richard S. Finn, Claude B. Sirlin, Michael M. Abecassis, Lewis R Roberts, Andrew X. Zhu, M Hassan Murad, and Jorge A. Marrero. AASLD guidelines for the treatment of hepatocellular carcinoma. *Hepatology*, 67(1):358–380, jan 2018.
- [66] Arie Regev, Mariana Berho, Lennox J. Jeffers, Clara Milikowski, Enrique G. Molina, Nikolaos T. Pyrsopoulos, Zheng Zhou Feng, K. Rajender Reddy, and Eugene R. Schiff. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. *American Journal of Gastroenterology*, 97(10):2614–2618, 2002.
- [67] Guido Colloredo, Maria Guido, Aurelio Sonzogni, and Gioacchino Leandro. Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: The smaller the sample, the milder the disease. *Journal of Hepatology*, 39(2):239–244, 2003.
- [68] P. Bedossa. Intraobserver and Interobserver Variations in Liver Biopsy Interpretation in Patients with Chronic Hepatitis C. *Hepatology*, 20(1):15–20, jul 1994.
- [69] Don C. Rockey, Stephen H. Caldwell, Zachary D. Goodman, Rendon C. Nelson, and Alastair D. Smith. Liver biopsy. *Hepatology*, 49(3):1017–1044, 2009.
- [70] Laurent Castera, Isabelle Negre, Kamran Samii, and Catherine Buffet. Patient-administered nitrous oxide/oxygen inhalation provides safe and effective analgesia for percutaneous liver biopsy: A randomized placebo-controlled trial. *The American Journal of Gastroenterology*, 96(5):1553–1557, 2001.
- [71] Leonard B. Seeff, Gregory T. Everson, Timothy R. Morgan, Teresa M. Curto, William M. Lee, Marc G. Ghany, Mitchell L. Shiffman, Robert J. Fontana, Adrian M. Di Bisceglie, Herbert L. Bonkovsky, and Jules L. Dienstag. Complication Rate of Percutaneous Liver Biopsies Among

Persons With Advanced Chronic Liver Disease in the HALT-C Trial. *Clinical Gastroenterology and Hepatology*, 8(10):877–883, 2010.

- [72] F. Piccinino, E. Sagnelli, G. Pasquale, G. Giusti, A. Battocchia, M. Bernardi, R. Bertolazzi, F.B. Bianchi, E. Brunelli, G. Budillon, L. Buscarini, A. Cargnel, G. Carrara, N. Carulli, L. Caruso, V. Cataldi, G. Celle, L. Chiandussi, L. Chiesa, M. Colombo, M. Coltorti, C. De Bac, C. Del Vecchio Blanco, G. Di Marco, F. Fiaccadori, M.G. Filippazzo, F. Fornari, A. Francavilla, M. Frezza, V. Gallo, V. Galvani, T. Givatto, C. Iannuzzi, C.M. Izzo, S. Le Moli, G. Longo, G. Magnani, M. Manai, F. Manenti, O. Manghisi, G. Manzillo, G. Marenco, F. Miglio, G. Molino, P.G. Mosca, R. Moschetta, C. Panella, G. Panichi, G. Parrilli, G. Pastore, C. Peluso, A. Picciotto, G. Pilleri, E. Pisi, M. Ponz de Leon, M. Rago, G. Raimondo, G. Realdi, M. Rizzetto, A. Rizzo, G. Ronchi, F. Rossi Fanelli, G. Ruggiero, N. Russo, A. Satta, D.E. Sansonno, C. Struglia, P. Tolentino, F. Tremolada, C. Trischitta, G. Verme, P. Viganò, G. Visco, and P. Zivelonghi. Complications following percutaneous liver biopsy. *Journal of Hepatology*, 2(2):165–173, 1986.
- [73] Masao Omata, Laurentius A. Lesmana, Ryosuke Tateishi, Pei Jer Chen, Shi Ming Lin, Haruhiko Yoshida, Masatoshi Kudo, Jeong Min Lee, Byung Ihn Choi, Ronnie T.P. Poon, Shuichiro Shiina, Ann Lii Cheng, Ji Dong Jia, Shuntaro Obi, Kwang Hyub Han, Wasim Jafri, Pierce Chow, Seng Gee Lim, Yogesh K. Chawla, Unggul Budihusodo, Rino A. Gani, C. Rinaldi Lesmana, Terawan Agus Putranto, Yun Fan Liaw, and Shiv Kumar Sarin. Asian pacific association for the study of the liver consensus recommendations on hepatocellular carcinoma. *Hepatology International*, 4(2):439–474, 2010.
- [74] Josep M. Llovet, Michel Ducreux, Riccardo Lencioni, Adrian M. Di Bisceglie, Peter R. Galle, Jean Francois Dufour, Tim F. Greten, Eric Raymond, Tania Roskams, Thierry De Baere, Michel Ducreux, Vincenzo Mazzaferro, Mauro Bernardi, Jordi Bruix, Massimo Colombo, and Andrew Zhu. EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma. *Journal of Hepatology*, 56(4):908–943, 2012.
- [75] Jordi Bruix and Morris Sherman. Management of hepatocellular carcinoma: An update. *Hepatology*, 53(3):1020–1022, 2011.
- [76] W. Schima, C. Kulinna, A. Ba-Ssalamah, and T. Grünberger. Multidetektor-CT (MDCT) der leber. *Radiologe*, 45(1):15–23, 2005.
- [77] Alex Frydrychowicz, Meghan G. Lubner, Jeffrey J. Brown, Elmar M. Merkle, Scott K. Nagle, Neil M. Rofsky, and Scott B. Reeder. Hepatobiliary MR imaging with gadolinium-based contrast agents. *Journal of Magnetic Resonance Imaging*, 35(3):492–511, 2012.

- [78] Roberto Miraglia, Giada Pietrosi, Luigi Maruzzelli, Ioannis Petridis, Settimo Caruso, Gianluca Marrone, Giuseppe Mamone, Giovanni Vizzini, Angelo Luca, and Bruno Gridelli. Predictive factors of tumor response to trans-catheter treatment in cirrhotic patients with hepatocellular carcinoma:A multivariate analysis of pre-treatment findings. *World Journal of Gastroenterology*, 13(45):6022–6026, 2007.
- [79] Myeong Jin Kim, Young Choi Jin, Seok Lim Joon, Yong Kim Jin, Hee Kim Joo, Taik Oh Young, Hye Yoo Eun, Joon Chung Jae, and Whang Kim Ki. Optimal scan window for detection of hypervascular hepatocellular carcinomas during MDCT examination. *American Journal of Roentgenology*, 187(1):198–206, 2006.
- [80] James P. Earls, Neil M. Rofsky, Douglas R. DeCorato, Glenn A. Krinsky, and Jeffrey C. Weinreb. Hepatic arterial-phase dynamic gadolinium-enhanced MR imaging: Optimization with a test examination and a power injector. *Radiology*, 202(1):268–273, 1997.
- [81] Jin Young Choi, Jeong Min Lee, and Claude B. Sirlin. CT and MR imaging diagnosis and staging of hepatocellular carcinoma. Part II. Extracellular agents, hepatobiliary agents, and ancillary imaging features. *Radiology*, 273(1):30–50, 2014.
- [82] Riccardo Iannaccone, Andrea Laghi, Carlo Catalane, Plinio Rossi, Filippo Mangiapane, Takamichi Murakami, Masatoshi Hori, Francesca Piacentini, Italo Nofroni, and Roberto Passariello. Hepatocellular carcinoma: Mole of unenhanced and delayed phase multi-detector mew helical CT in patients with cirrhosis. *Radiology*, 234(2):460–467, 2005.
- [83] Jordi Rimola, Alejandro Forner, Maria Reig, Ramon Vilana, Carlos Rodríguez De Lope, Carmen Ayuso, and Jordi Bruix. Cholangiocarcinoma in cirrhosis: Absence of contrast washout in delayed phases by magnetic resonance imaging avoids misdiagnosis of hepatocellular carcinoma. *Hepatology*, 50(3):791–798, 2009.
- [84] Yuko Nakamura, Naoyuki Toyota, Shuji Date, Seitaro Oda, Tomohiro Namimoto, Yasuyuki Yamashita, Toru Beppu, and Kazuo Awai. Clinical significance of the transitional phase at gadoxetate disodium-enhanced hepatic MRI for the diagnosis of hepatocellular carcinoma: Preliminary results. *Journal of Computer Assisted Tomography*, 35(6):723–727, 2011.
- [85] Yukihisa Takayama, Akihiro Nishie, Tomohiro Nakayama, Yoshiki Asayama, Kousei Ishigami, Daisuke Kakihara, Yasuhiro Ushijima, Nobuhiro Fujita, Masakazu Hirakawa, and Hiroshi Honda. Hypovascular hepatic nodule showing hypointensity in the hepatobiliary phase of gadoxetic acid-enhanced MRI in patients with chronic liver disease: Prediction of malignant transformation. *European Journal of Radiology*, 81(11):3072–3078, 2012.

- [86] Takashi Kumada, Hidenori Toyoda, Toshifumi Tada, Yasuhiro Sone, Masashi Fujimori, Sadanobu Ogawa, and Teruyoshi Ishikawa. Evolution of hypointense hepatocellular nodules observed only in the hepatobiliary phase of gadoxetate disodium-enhanced MRI. *American Journal of Roentgenology*, 197(1):58–63, 2011.
- [87] Satoshi Kobayashi, Osamu Matsui, Toshifumi Gabata, Wataru Koda, Tetsuya Minami, Yasuji Ryu, Kazuto Kozaka, and Azusa Kitao. Relationship between signal intensity on hepatobiliary phase of gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid (Gd-EOB-DTPA)-enhanced MR imaging and prognosis of borderline lesions of hepatocellular carcinoma. *European Journal of Radiology*, 81(11):3002–3009, 2012.
- [88] Young Kon Kim, Won Jae Lee, Min Jung Park, Seong Hyun Kim, Hyunchul Rhim, and Dongil Choi. Hypovascular hypointense nodules on hepatobiliary phase gadoxetic acid-enhanced MR images in patients with cirrhosis: Potential of DW imaging in predicting progression to hypervascular HCC. *Radiology*, 265(1):104–114, 2012.
- [89] Tomoko Hyodo, Takamichi Murakami, Yasuharu Imai, Masahiro Okada, Masatoshi Hori, Yuki Kagawa, Sachiko Kogita, Seishi Kumano, Masatoshi Kudo, and Teruhito Mochizuki. Hypovascular nodules in patients with chronic liver disease: Risk factors for development of hypervascular hepatocellular carcinoma. *Radiology*, 266(2):480–490, 2013.
- [90] Min Jung Park, Young Kon Kim, Min Woo Lee, Won Jae Lee, Young Sun Kim, Seong Hyun Kim, Dongil Choi, and Hyunchul Rhim. Small hepatocellular carcinomas: Improved sensitivity by combining gadoxetic acid-enhanced and diffusion-weighted MR imaging patterns. *Radiology*, 264(3):761–770, 2012.
- [91] Seong Hyun Kim, Seung Hoon Kim, Jongmee Lee, Min Ju Kim, Yong Hwan Jeon, Yulri Park, Dongil Choi, Won Jae Lee, and Hyo K. Lim. Gadoxetic Acid–Enhanced MRI Versus Triple-Phase MDCT for the Preoperative Detection of Hepatocellular Carcinoma. *American Journal of Roentgenology*, 192(6):1675–1681, jun 2009.
- [92] Josep M. Llovet, Adrian M. Di Bisceglie, Jordi Bruix, Barnett S. Kramer, Riccardo Lencioni, Andrew X. Zhu, Morris Sherman, Myron Schwartz, Michael Lotze, Jayant Talwalkar, and Gregory J. Gores. Design and endpoints of clinical trials in hepatocellular carcinoma. *Journal of the National Cancer Institute*, 100(10):698–711, 2008.
- [93] RN Pugh, IM Murray-Lyon, JL Dawson, MC Pietroni, and R Williams. Transection of the oesophagus for bleeding oesophageal varices. *The British journal of surgery*, 60(8):646—649, August 1973.

- [94] M. M. Oken, R. H. Creech, and T. E. Davis. Toxicology and response criteria of the Eastern Cooperative Oncology Group, 1982.
- [95] VINCENZO Mazzaferro, ENRICO REGALIA, ROBERTO DOCI, SALVATORE ANDREOLA, ANDREA PULVIRENTI, FEDERICO BOZZETTI, FABRIZIO MONTALTO, MARIO AMMATUNA, ALBERTO MORABITO, and LEANDRO GENNARI. Carcinomas in Patients With Cirrhosis. *The New England Journal of Medicine*, 334(11):693–699, 1996.
- [96] Stephen B. Edge and Carolyn C. Compton. The american joint committee on cancer: The 7th edition of the AJCC cancer staging manual and the future of TNM. *Annals of Surgical Oncology*, 17(6):1471–1474, 2010.
- [97] Tian Yang, Chuan Lin, Jian Zhai, Song Shi, Min Zhu, Nan Zhu, Jun Hua Lu, Guang Shun Yang, and Meng Chao Wu. Surgical resection for advanced hepatocellular carcinoma according to Barcelona Clinic Liver Cancer (BCLC) staging. *Journal of Cancer Research and Clinical Oncology*, 138(7):1121–1129, 2012.
- [98] C. Verslype, O. Rosmorduc, and P. Rougier. Hepatocellular carcinoma: ESMO-ESDO clinical practice guidelines for diagnosis, treatment and follow-up. *Annals of Oncology*, 23(SUPPL. 7), 2012.
- [99] Vincenzo Mazzaferro, Sherrie Bhoozi, Carlo Sposito, Marco Bongini, Martin Langer, Rosalba Miceli, and Luigi Mariani. Milan criteria in liver transplantation for hepatocellular carcinoma: An evidence-based analysis of 15 years of experience. *Liver Transplantation*, 17(S2):S44–S57, oct 2011.
- [100] Josep M. Llovet, Josep Fuster, and Jordi Bruix. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: Resection versus transplantation. *Hepatology*, 30(6):1434–1440, 1999.
- [101] Alejandro Forner, Josep M. Llovet, and Jordi Bruix. Hepatocellular carcinoma. *The Lancet*, 379(9822):1245–1255, 2012.
- [102] David J. Breen and Riccardo Lencioni. Image-guided ablation of primary liver and renal tumours. *Nature Reviews Clinical Oncology*, 12(3):175–186, 2015.
- [103] Stéphanie Perrodin, Anja Lachenmayer, Martin Maurer, Corina Kim-Fuchs, Daniel Candinas, and Vanessa Banz. Percutaneous stereotactic image-guided microwave ablation for malignant liver lesions. *Scientific Reports*, 9(1):1–8, 2019.

- [104] Reto Bale, Peter Schullian, Gernot Eberle, Daniel Putzer, Heinz Zoller, Stefan Schneeberger, Claudia Manzl, Patrizia Moser, and Georg Oberhuber. Stereotactic Radiofrequency Ablation of Hepatocellular Carcinoma: a Histopathological Study in Explanted Livers. *Hepatology*, 70(3):840–850, 2019.
- [105] Gregor Laimer, Peter Schullian, Nikolai Jaschke, Daniel Putzer, Gernot Eberle, Amilcar Alzaga, Bruno Odisio, and Reto Bale. Minimal ablative margin (MAM) assessment with image fusion: an independent predictor for local tumor progression in hepatocellular carcinoma after stereotactic radiofrequency ablation. *European Radiology*, 30(5):2463–2472, 2020.
- [106] Marta Burrel, María Reig, Alejandro Forner, Marta Barrufet, Carlos Rodríguez De Lope, Silvia Tremosini, Carmen Ayuso, Josep M. Llovet, María Isabel Real, and Jordi Bruix. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design. *Journal of Hepatology*, 56(6):1330–1335, 2012.
- [107] E A Eisenhauer, P Therasse, J Bogaerts, L H Schwartz, D Sargent, R Ford, J Dancey, S Arbuck, S Gwyther, M Mooney, L Rubinstein, L Shankar, and L Dodd. New response evaluation criteria in solid tumours : Revised RECIST guideline (version 1 . 1). *European Journal of Cancer*, 45(2):228–247, 2008.
- [108] S. Turdean, Simona Gurzu, M. Turcu, S. Voidazan, and Anca Sin. Current data in clinicopathological characteristics of primary hepatic tumors. *Romanian Journal of Morphology and Embryology*, 53(3 SUPPL.):719–724, 2012.